Broncus Holding Corp. (HK:2216) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Broncus Holding Corp. reports a significant 46% reduction in net loss for the first half of 2024 compared to the previous year, due to cost optimizations in production and R&D. The company is making strides in the Chinese market with its lung disease surgery consumables, as its products gain traction in hospitals across the country. Notably, the InterVapor Thermal Vapor Treatment System is widely recognized for its effectiveness and is now commercially used in over 60 hospitals in China.
For further insights into HK:2216 stock, check out TipRanks’ Stock Analysis page.